49711-14-0

Upstream product

• 141-82-2 malonic acid 
• 66-99-9 β-naphthaldehyde 
• 108-24-7 acetic anhydride 
• 124182-61-2 trans-3-(2-naphthyl)-propenoic acid butyl ester 
• 688-49-3 ethyl (diethoxyphosphino)acetate 
• 110-16-7 maleic acid 
• 79-10-7 acrylic acid 
• 114833-06-6 ethyl (E)-3-(naphthalene-2-yl)acrylate 
• 3095-95-2 diethylphosphonoacetic acid 
• 612-55-5 2-iodonaphthalene 
• 93-11-8 2-Naphthalenesulfonyl chloride 
• 613-46-7 2-naphthalenecarbonitrile 
• 558-13-4 carbon tetrabromide 
• 827-54-3 2-naphthylethylene 

Downstream Products

• 20883-90-3 methyl (E)-3-(naphthalen-2-yl)acrylate 
• 125542-26-9 (E)-N-Hydroxy-3-naphthalen-2-yl-N-p-tolyl-acrylamide 
• 85992-27-4 3-chloronaphtho<1,2-b>thiophene-2-carbonyl chloride 
• 105847-13-0 N-phenyl 3-(2-naphthyl)acrylohydroxamic acid 
• 105847-12-9 N-cyclohexyl 3-(2-naphthyl)acrylohydroxamic acid 
• 848250-71-5 C₄₄H₄₆O₁₂ 
• 301659-87-0 (R)-4-Benzyl-3-((E)-3-naphthalen-2-yl-acryloyl)-oxazolidin-2-one 
• 301659-88-1 (S)-4-Benzyl-3-((E)-3-naphthalen-2-yl-acryloyl)-oxazolidin-2-one 
• 192070-75-0 (R)-N-[trans-3-(2-naphthyl)propenoyl]-4-phenyl-1,3-oxazolidin-2-one 
• 21461-46-1 (E)-2-(2-nitrovinyl)naphthalene 
• 872852-75-0 C₄₃H₄₆O₁₂ 

Relevant academic research and scientific papers

Construction and activity evaluation of novel dual-target (SE/CYP51) anti-fungal agents containing amide naphthyl structure

With the increase of fungal infection and drug resistance, it is becoming an urgent task to discover the highly effective antifungal drugs. In the study, we selected the key ergosterol bio-synthetic enzymes (Squalene epoxidase, SE; 14 α-demethylase, CYP51) as dual-target receptors to guide the construction of novel antifungal compounds, which could achieve the purpose of improving drug efficacy and reducing drug-resistance. Three different series of amide naphthyl compounds were generated through the method of skeleton growth, and their corresponding target products were synthesized. Most of compounds displayed the obvious biological activity against different Candida spp. and Aspergillus fumigatus. Among of them, target compounds 14a-2 and 20b-2 not only possessed the excellent broad-spectrum anti-fungal activity (MIC50, 0.125–2 μg/mL), but also maintained the anti-drug-resistant fungal activity (MIC50, 1–4 μg/mL). Preliminary mechanism study revealed the compounds (14a-2, 20b-2) could block the bio-synthetic pathway of ergosterol by inhibiting the dual-target (SE/CYP51) activity, and this finally caused the cleavage and death of fungal cells. In addition, we also discovered that compounds 14a-2 and 20b-2 with low toxic and side effects could exert the excellent therapeutic effect in mice model of fungal infection, which was worthy for further in-depth study.

Visible-light promoted oxidative cyclization of cinnamic acid derivatives using xanthone as the photocatalyst

We have developed an efficient photocatalytic synthesis of coumarin derivativesviaa tandem double bond isomerization/oxidative cyclization of cinnamic acids. Inexpensive and stable xanthone was used as the photocatalyst, and readily available Selectfluor was used as the oxidant. This method tolerates a wide range of functional groups and offers excellent chemical yields in general. Besides, the photocatalytic oxidative cyclization of cinnamic acid esters gives dimerized lignan-type products.

Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors

Ergosterol as the core component of fungal cell membrane plays a key role in maintaining cell morphology and permeability. The squalenee epoxidase (SE) and 14-demethylase (CYP51) are the important rate-limiting enzymes for ergosterol synthesis. In the study, these active fragments, which is derived from the structural groups of the common antifungal agents, were docked into the active sites of dual targets (SE, CYP51), respectively. Some of active fragments with the matching MCSS_Score values were selected and connected to construct three different series of novel arylalkene-amide derivatives as dual-target (SE, CYP51) antifungal inhibitors. Subsequently, these compounds were further synthesized, and their bioactivity was evaluated. Most of compounds showed a certain degree of antifungal activity in vitro. It was worth noting that the target compounds 17a and 25a with excellent antifungal activity (0.125–4 μg/mL) can inhibit the fluconazole-resistant Candida Strain 17#, CaR, 632, and 901 in the range of MIC values (4–8 μg/mL). Furthermore, their molecular mechanism, structural stability and low toxicity were further confirmed. The molecular docking and ADMET properties were predicted to guide the subsequent optimization of target compounds.

Aryl amide derivatives and application thereof

The invention belongs to the field of drug synthesis, and relates to a novel aryl amide derivative. The invention relates to a strong antifungal effect of aryl amide derivatives, and also relates to applications of the compounds and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof in preparation of medicines for treating fungal diseases, especially applications of medicines for treating and preventing pathogenic drug-resistant fungi. The invention provides a general formula shown in the specification.

Aryl olefin azole derivative as well as preparation method and application thereof

The invention belongs to the technical field of medicines, and relates to an aryl olefin azole derivative shown in a general formula I, stereoisomers thereof and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, and substituent groups Ar, R and X have definitions given in the specification. The invention also relates to a method for preparing the compound as shown in the general formula I, a medicinal composition containing the compound and application of the compound and the medicinal composition in preparation of medicines for treating and preventing superficial fungal and deep fungal diseases.

N-substituted acrylamide derivatives as DHODH inhibitors and preparation and use of N-substituted acrylamide derivatives

The invention relates to N-substituted acrylamide derivatives as DHODH inhibitors and preparation and use of the N-substituted acrylamide derivatives. In particular, the invention discloses a compoundshown in a general formula I and the preparation and use of the compound. The compound has excellent DHODH inhibitory activation, so the compound can be used for treating or preventing various diseases caused by DHODH, the various diseases include but not limited to cancer, rheumatoid arthritis, lupus erythematosus, organ transplant rejection and other autoimmune diseases, and colitis, rhinitis and other inflammatory diseases.

Tailored Mutants of Phenylalanine Ammonia-Lyase from Petroselinum crispum for the Synthesis of Bulky l- and d-Arylalanines

Tailored mutants of phenylalanine ammonia-lyase from Petroselinum crispum (PcPAL) were created and tested in ammonia elimination from various sterically demanding, non-natural analogues of phenylalanine and in ammonia addition reactions into the corresponding (E)-arylacrylates. The wild-type PcPAL was inert or exhibited quite poor conversions in both reactions with all members of the substrate panel. Appropriate single mutations of residue F137 and the highly conserved residue I460 resulted in PcPAL variants that were active in ammonia elimination but still had a poor activity in ammonia addition onto bulky substrates. However, combined mutations that involve I460 besides the well-studied F137 led to mutants that exhibited activity in ammonia addition as well. The synergistic multiple mutations resulted in substantial substrate scope extension of PcPAL and opened up new biocatalytic routes for the synthesis of both enantiomers of valuable phenylalanine analogues, such as (4-methoxyphenyl)-, (napthalen-2-yl)-, ([1,1′-biphenyl]-4-yl)-, (4′-fluoro-[1,1′-biphenyl]-4-yl)-, and (5-phenylthiophene-2-yl)alanines.

Transition-metal-free C-P bond formation via decarboxylative phosphorylation of cinnamic acids with P(O)H compounds

A novel, transition-metal-free phosphorylation of cinnamic acids with P(O)H compounds has been developed via radical-promoted decarboxylation under mild conditions. This method provides simple, efficient, and versatile access to valuable (E)-alkenylphosphine oxides in satisfactory yields with a wide variety of substrates.

Carboxylation of styrenes with CBr4 and DMSO via cooperative photoredox and cobalt catalysis

Cooperative photoredox and cobalt catalyzed carboxylation of styrenes with CBr4 to afford the corresponding α,β-unsaturated carboxylic acids has been realized through radical addition and Kornblum (DMSO) oxidation. DMSO serves as the oxidant, oxygen source and solvent under these photocatalytic conditions.

Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids

Matriptase-2, a type II transmembrane serine protease (TTSP), is expressed in the liver and regulates iron homeostasis via the cleavage of hemojuvelin. Matriptase-2 emerges as an attractive target for the treatment of conditions associated with iron overload, such as hemochromatosis or beta-thalassemia. Starting from the crystal structure of its closest homolog matriptase, we constructed a homology model of matriptase-2 in order to further optimize the selectivity of serine trap peptidomimetic inhibitors for matriptase-2 vs matriptase. Careful modifications of the P4, P3 and P2 positions with the help of unnatural amino acids led to a thorough understanding of Structure-Activity Relationship and a >60-fold increase in selectivity for matriptase-2 vs matriptase. Additionally, the introduction of unnatural amino acids led to significant increases in plasma stability. Such compounds represent useful pharmacological tools to test matriptase-2 inhibition in a context of iron overload.